Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 20:54:32 16/07/2024 BST			5-day change	1st Jan Change
0.96 ^USD	+53.74%		-8.57%	-86.74%

06-30	Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	CI
06-12	Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	CI

ARCH THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

January 04, 2021 at 12:57 pm

Item 7.01 Regulation FD Disclosure.

On January 4, 2021, Arch Therapeutics, Inc. (the "Company") issued a press release announcing its entrance into a distribution and sales administration agreement with Buffalo Supply, Inc. ("BSI"), pursuant to which BSI will serve as the Company's exclusive distributor for products sold to United States government facilities worldwide.

The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit Description

99.1 Press Release issued by Arch Therapeutics, Inc. on January 4, 2021

Latest news about Arch Therapeutics, Inc.

Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	06-29	CI
Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	06-11	CI
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding	05-14	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-09	CI
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	05-06	CI
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-20	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	02-15	CI
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	11-02	CI
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	13/09/23	CI
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding	30/08/23	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	11/08/23	CI
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding	06/07/23	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23/05/23	CI
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care	25/04/23	CI
Arch Therapeutics, Inc. Announces Dedicated HCPCS Billing Code for its Advanced Wound System Now in Effect	05/04/23	CI
Arch Therapeutics' AC5(R) Advanced Wound System Receives Dedicated HCPCS Billing Code from the Centers for Medicare & Medicaid Services	09/03/23	CI
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of Ac5® Advanced Wound System in Government Facilities	07/03/23	CI
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	14/02/23	CI
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System	18/01/23	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	28/12/22	CI
Arch Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	27/12/22	CI
Arch Therapeutics Announces First Shipments of Ac5® Advanced Wound System Under New Reimbursement Support Program	23/09/22	CI
Arch Therapeutics, Inc. Launches Multi-Site Clinical Study for AC5® Advanced Wound System	07/09/22	CI
Arch Therapeutics, Inc. Submits Application to Centers for Medicare and Medicaid Services for Ac5® Advanced Wound System	01/09/22	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	11/08/22	CI

Chart Arch Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Medical Devices & Implants

	1st Jan change	Capi.
ARCH THERAPEUTICS, INC.	-86.74%	4.27M
STRYKER CORPORATION	+13.57%	127B
SMITH & NEPHEW PLC	+1.02%	12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-18.47%	6.88B
GLAUKOS CORPORATION	+55.23%	6.86B
AXONICS, INC.	+9.22%	3.47B
ENOVIS CORPORATION	-15.66%	2.54B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-18.25%	1.9B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-27.00%	1.58B
DOUBLE MEDICAL TECHNOLOGY INC.	-37.52%	1.43B

Medical Devices & Implants